, Tracking Stock Market Picks
Enter Symbol:
Dynavax Technologies Corporation (DVAX) [hlAlert]

down 37.47 %

Dynavax Technologies Corporation (DVAX) rated Buy

Posted on: Wednesday,  Oct 3, 2007  9:25 AM ET by Credit Suisse

Credit Suisse rated Buy Dynavax Technologies Corporation (NASDAQ: DVAX) on 10/03/2007, when the stock price was $45.50. Since
then, Dynavax Technologies Corporation has lost 37.47% as of 01/27/2016's recent price of $28.45.
If you would have followed this Credit Suisse's recommendation on DVAX, you would have lost 37.47% of your investment in 3038 days.

Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.

Excellence in equity and fixed income research is a hallmark of Credit Suisse. Globally, our equity research analysts provide in-depth coverage of over 2,500 companies and engage in a knowledge-sharing, value added culture that has yielded the most insightful product for our customers and tremendous competitive results. Additionally, Credit Suisse's powerful macro-economic and debt strategy teams integrate the bank's comprehensive company research with keen market perspectives of the ever-shifting investment terrain.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/3/2007 9:25 AM Buy
45.50 80.00
as of 8/27/2015
1 Week up  5.17 %
1 Month up  28.73 %
3 Months up  39.46 %
1 YTD up  45.15 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy